RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fs0140-6736
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fs0140-6736
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
prism:doi |
10.1016/s0140-6736 |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
prism:doi |
10.1016/s0140-6736 |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
prism:doi |
10.1016/s0140-6736 |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
prism:doi |
10.1016/s0140-6736 |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
prism:doi |
10.1016/s0140-6736 |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
dcterms:title |
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
dcterms:title |
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
dcterms:title |
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
dcterms:title |
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
dcterms:title |
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
dcterms:title |
European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
dcterms:title |
European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
dcterms:title |
European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
dcterms:title |
European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
dcterms:title |
European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
dcterms:title |
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
dcterms:title |
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
dcterms:title |
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
dcterms:title |
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
dcterms:title |
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
dcterms:title |
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
dcterms:title |
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
dcterms:title |
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
dcterms:title |
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
dcterms:title |
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
dcterms:title |
The primary health-care system in China |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
dcterms:title |
The primary health-care system in China |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
dcterms:title |
The primary health-care system in China |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
dcterms:title |
The primary health-care system in China |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
dcterms:title |
The primary health-care system in China |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
rdf:type |
node1 |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
rdf:type |
node1 |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
rdf:type |
node1 |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
rdf:type |
node1 |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
rdf:type |
node1 |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
owl:sameAs |
https://semopenalex.org/work/W2594075087 |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
owl:sameAs |
https://semopenalex.org/work/W2594075087 |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
owl:sameAs |
https://semopenalex.org/work/W2594075087 |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
owl:sameAs |
https://semopenalex.org/work/W2594075087 |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
owl:sameAs |
https://semopenalex.org/work/W2594075087 |
ripekg:work/10.1136%2Fbmj-2024-082765A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1136%2Fbmj-2024-082765A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1136%2Fbmj-2024-082765A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1136%2Fbmj-2024-082765A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1136%2Fbmj-2024-082765A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |
ripekg:work/10.1136%2Fbmj-2025-084539Effect of lateral versus supine positioning on hypoxaemia in sedated adults: multicentre randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial |
ripekg:work/10.1136%2Fbmj-2025-084539Effect of lateral versus supine positioning on hypoxaemia in sedated adults: multicentre randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study |
ripekg:work/10.1136%2Fbmj-2025-084539Effect of lateral versus supine positioning on hypoxaemia in sedated adults: multicentre randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 |
ripekg:work/10.1136%2Fbmj-2025-084539Effect of lateral versus supine positioning on hypoxaemia in sedated adults: multicentre randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial |
ripekg:work/10.1136%2Fbmj-2025-084539Effect of lateral versus supine positioning on hypoxaemia in sedated adults: multicentre randomised controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs0140-6736The primary health-care system in China |